The recent development of novel, long-acting antibiotics has prompted exploration in the infectious disease literature of their use for cellulitis in the ED to decrease hospitalizations” Koziatek et al (2017).

Abstract:

Cellulitis is frequently encountered in the emergency department (ED) and is estimated to result in over 700,000 hospital admissions per year [1-3]. The recent development of novel, long-acting antibiotics has prompted exploration in the infectious disease literature of their use for cellulitis in the ED to decrease hospitalizations [4-6]. Dalbavancin is a semisynthetic lipoglycopeptide antibiotic with activity against gram-positive pathogens largely responsible for cellulitis, including methicillin-resistant Staphylococcus aureus (MRSA) [7].

Reference:


DOI: http://dx.doi.org/10.1016/j.ajem.2017.11.037

Thank you to our partners for supporting IVTEAM